Works matching DE "PEMBROLIZUMAB"
Results: 1217
Update on safety and feasibility of the combination of pembrolizumab and pelvic chemoradiation in locally advanced cervical cancer.
- Published in:
- Cancer (0008543X), 2025, v. 131, n. 4, p. 1, doi. 10.1002/cncr.35757
- By:
- Publication type:
- Article
Pembrolizumab with chemoradiotherapy followed by pembrolizumab for stage III–IVa cervical cancer: is the ENGOT‐cx11/GOG‐3047/KEYNOTE‐A18 trial practice changing?
- Published in:
- Cancer (0008543X), 2025, v. 131, n. 4, p. 1, doi. 10.1002/cncr.35749
- By:
- Publication type:
- Article
A Case of Rapidly Progressing Urothelial Carcinoma Arising After Living Donor Kidney Transplantation Treated with Chemotherapy and Immune Checkpoint Inhibitors.
- Published in:
- Yonago Acta Medica, 2025, v. 68, n. 1, p. 75, doi. 10.33160/yam.2025.02.009
- By:
- Publication type:
- Article
First Report of Pembrolizumab Activity in KIT-Mutated Thymic Carcinoma.
- Published in:
- Current Oncology, 2025, v. 32, n. 2, p. 68, doi. 10.3390/curroncol32020068
- By:
- Publication type:
- Article
Haemorrhage-related adverse events profles of lenvatinib and pembrolizumab alone or in combination: a real-world pharmacovigilance study based on FAERS database.
- Published in:
- BMC Pharmacology & Toxicology, 2025, v. 26, n. 1, p. 1, doi. 10.1186/s40360-025-00878-3
- By:
- Publication type:
- Article
Vibration properties of immune‐oncological drugs.
- Published in:
- Journal of Raman Spectroscopy, 2022, v. 53, n. 4, p. 715, doi. 10.1002/jrs.6297
- By:
- Publication type:
- Article
Incidence and risk factors of acute kidney injury, and its effect on mortality among Japanese patients receiving immune check point inhibitors: a single-center observational study.
- Published in:
- Clinical & Experimental Nephrology, 2021, v. 25, n. 5, p. 479, doi. 10.1007/s10157-020-02008-1
- By:
- Publication type:
- Article
Pembrolizumab in Recurrent Squamous Cell Carcinoma of the Vulva: Case Report and Review of the Literature.
- Published in:
- 2019
- By:
- Publication type:
- journal article
Tumour-immune dynamics with an immune checkpoint inhibitor.
- Published in:
- Letters in Biomathematics, 2018, v. 5, p. S137, doi. 10.1080/23737867.2018.1440978
- By:
- Publication type:
- Article
American Association of Cancer Research Showcases Immunotherapy Advances.
- Published in:
- JNCI: Journal of the National Cancer Institute, 2015, v. 107, n. 8, p. 4, doi. 10.1093/jnci/djv231
- By:
- Publication type:
- Article
PDQ (Physician Data Query).
- Published in:
- 2014
- Publication type:
- Abstract
Transient altered mental status and leptomeningeal enhancement associated with pembrolizumab: a case report.
- Published in:
- 2021
- By:
- Publication type:
- Letter
Clinical and magnetic resonance imaging monitoring in progressive multifocal leukoencephalopathy treated with pembrolizumab: a case report.
- Published in:
- 2021
- By:
- Publication type:
- Case Study
Long Noncoding RNA Hotair Promotes the Progression and Immune Escape in Laryngeal Squamous Cell Carcinoma through MicroRNA-30a/GRP78/PD-L1 Axis.
- Published in:
- 2022
- By:
- Publication type:
- journal article
Pembrolizumab dramatically resolves choroidal metastatis from esophageal adenocarcinoma and restores vision: a case report.
- Published in:
- Oxford Medical Case Reports, 2021, v. 2021, n. 6, p. 1, doi. 10.1093/omcr/omab047
- By:
- Publication type:
- Article
Health-Related Quality of Life with Pembrolizumab in Patients with Locally Advanced or Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma: KEYNOTE-629.
- Published in:
- Dermatology & Therapy, 2023, v. 13, n. 12, p. 3165, doi. 10.1007/s13555-023-01059-y
- By:
- Publication type:
- Article
Preclinical comparison of prolgolimab, pembrolizumab and nivolumab.
- Published in:
- Scientific Reports, 2024, v. 14, n. 1, p. 1, doi. 10.1038/s41598-024-72118-3
- By:
- Publication type:
- Article
Preclinical comparison of prolgolimab, pembrolizumab and nivolumab.
- Published in:
- Scientific Reports, 2024, v. 14, n. 1, p. 1, doi. 10.1038/s41598-024-72118-3
- By:
- Publication type:
- Article
PD-L1 expression as a predictive biomarker in patients with recurrent or metastatic salivary gland carcinoma treated with pembrolizumab.
- Published in:
- Scientific Reports, 2024, v. 14, n. 1, p. 1, doi. 10.1038/s41598-024-70779-8
- By:
- Publication type:
- Article
PD-1/PD-L1 Inhibitors in Cervical Cancer.
- Published in:
- Frontiers in Pharmacology, 2019, p. N.PAG, doi. 10.3389/fphar.2019.00065
- By:
- Publication type:
- Article
Current Understanding of the Mechanisms Underlying Immune Evasion From PD-1/PD-L1 Immune Checkpoint Blockade in Head and Neck Cancer.
- Published in:
- Frontiers in Oncology, 2020, p. 1, doi. 10.3389/fonc.2020.00268
- By:
- Publication type:
- Article
Potential Immune-Related Adverse Events Associated With Monotherapy and Combination Therapy of Ipilimumab, Nivolumab, and Pembrolizumab for Advanced Melanoma: A Systematic Review and Meta-Analysis.
- Published in:
- Frontiers in Oncology, 2020, v. 10, p. 1, doi. 10.3389/fonc.2020.00091
- By:
- Publication type:
- Article
Pembrolizumab Induced Ocular Hypotony With Near Complete Vision Loss, Interstitial Pulmonary Fibrosis and Arthritis.
- Published in:
- Frontiers in Oncology, 2019, p. 1, doi. 10.3389/fonc.2019.00944
- By:
- Publication type:
- Article
Effect of Radiotherapy Combined With Pembrolizumab on Local Tumor Control in Mucosal Melanoma Patients.
- Published in:
- Frontiers in Oncology, 2019, p. 1, doi. 10.3389/fonc.2019.00835
- By:
- Publication type:
- Article
Pembrolizumab in a Patient With a Metastatic CASTLE Tumor of the Parotid.
- Published in:
- Frontiers in Oncology, 2019, p. 1, doi. 10.3389/fonc.2019.00734
- By:
- Publication type:
- Article
Chemotherapy in Combination With Immune Checkpoint Inhibitors for the First-Line Treatment of Patients With Advanced Non-small Cell Lung Cancer: A Systematic Review and Literature-Based Meta-Analysis.
- Published in:
- Frontiers in Oncology, 2019, p. N.PAG, doi. 10.3389/fonc.2019.00264
- By:
- Publication type:
- Article
Rescue of Immunotherapy-Refractory Metastatic Merkel Cell Carcinoma With Conventionally Fractionated Radiotherapy and Concurrent Pembrolizumab.
- Published in:
- Frontiers in Oncology, 2019, p. N.PAG, doi. 10.3389/fonc.2019.00223
- By:
- Publication type:
- Article
Inflammatory Arthritis Induced by Pembrolizumab in a Patient With Head and Neck Squamous Cell Carcinoma.
- Published in:
- 2018
- By:
- Publication type:
- Case Study
<italic>In‐vitro</italic> effect of pembrolizumab on different T regulatory cell subsets.
- Published in:
- Clinical & Experimental Immunology, 2018, v. 191, n. 2, p. 189, doi. 10.1111/cei.13060
- By:
- Publication type:
- Article
Recurrent Sympathetic Ophthalmia with Annular Choroidal Detachment after Pembrolizumab Treatment: A Case Report.
- Published in:
- Ocular Immunology & Inflammation, 2020, v. 28, n. 6, p. 864, doi. 10.1080/09273948.2019.1604975
- By:
- Publication type:
- Article
Management of Chronic Hypotony Following Bilateral Uveitis in a Patient Treated with Pembrolizumab for Cutaneous Metastatic Melanoma.
- Published in:
- 2019
- By:
- Publication type:
- journal article
Correlation of Immune-Related Adverse Events and Effects of Pembrolizumab Monotherapy in Patients with Non-Small Cell Lung Cancer.
- Published in:
- Lung Cancer: Targets & Therapy, 2020, v. 11, p. 53, doi. 10.2147/LCTT.S254146
- By:
- Publication type:
- Article
Pembrolizumab in the treatment of metastatic non-small-cell lung cancer: patient selection and perspectives.
- Published in:
- Lung Cancer: Targets & Therapy, 2017, v. 8, p. 1, doi. 10.2147/LCTT.S105678
- By:
- Publication type:
- Article
Targeting PD-I/PD-LI in lung cancer: current perspectives.
- Published in:
- Lung Cancer: Targets & Therapy, 2015, v. 6, p. 55, doi. 10.2147/LCTT.S55176
- By:
- Publication type:
- Article
Metastatic Urothelial Carcinoma from Transplanted Kidney with Complete Response to an Immune Checkpoint Inhibitor.
- Published in:
- Case Reports in Urology, 2020, p. 1, doi. 10.1155/2020/8881841
- By:
- Publication type:
- Article
Bayesian Hierarchical Modelling for Histology-Independent Time-to-Event Outcomes in the NICE Single Technology Appraisal of Pembrolizumab for Solid Tumours with MSI-H/dMMR: External Assessment Group Perspective.
- Published in:
- PharmacoEconomics, 2024, v. 42, n. 6, p. 615, doi. 10.1007/s40273-024-01381-z
- By:
- Publication type:
- Article
Cost Effectiveness of Adding Pembrolizumab to Platinum and Fluoropyrimidine-Based Chemotherapy as First-Line Treatment for Advanced Esophageal Cancer: A US Healthcare Payer's Perspective.
- Published in:
- PharmacoEconomics, 2022, v. 40, n. 12, p. 1247, doi. 10.1007/s40273-022-01196-w
- By:
- Publication type:
- Article
Pembrolizumab for Treating Relapsed or Refractory Classical Hodgkin Lymphoma: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
- Published in:
- 2019
- By:
- Publication type:
- journal article
Pembrolizumab for Locally Advanced or Metastatic Urothelial Cancer Where Cisplatin is Unsuitable: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
- Published in:
- 2019
- By:
- Publication type:
- journal article
Q-TWiST Analysis to Assess Benefit-Risk of Pembrolizumab in Patients with PD-L1-Positive Advanced or Metastatic Non-small Cell Lung Cancer.
- Published in:
- 2019
- By:
- Publication type:
- journal article
Pembrolizumab for Previously Treated Advanced or Metastatic Urothelial Cancer: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
- Published in:
- 2019
- By:
- Publication type:
- journal article
Cost Effectiveness of Pembrolizumab vs. Standard-of-Care Chemotherapy as First-Line Treatment for Metastatic NSCLC that Expresses High Levels of PD-L1 in the United States.
- Published in:
- 2017
- By:
- Publication type:
- journal article
Prognostic Model of Baseline Medications plus Neutrophil-to-lymphocyte Ratio in Patients with Advanced Non-small-cell Lung Cancer Receiving Immune Checkpoint Inhibitor plus Platinum Doublet: A Multicenter Retrospective Study.
- Published in:
- Journal of Cancer, 2023, v. 14, n. 5, p. 676, doi. 10.7150/jca.80517
- By:
- Publication type:
- Article
Lymphocytic gastritis induced by pembrolizumab in a patient with metastatic melanoma: A case report.
- Published in:
- Canadian Journal of Pathology, 2018, v. 10, p. 16
- By:
- Publication type:
- Article
Development and characterization of single domain monoclonal antibody against programmed cell death ligand-1; as a cancer inhibitor candidate.
- Published in:
- Iranian Journal of Basic Medical Sciences, 2022, v. 25, n. 3, p. 313, doi. 10.22038/IJBMS.2022.62522.13834
- By:
- Publication type:
- Article
High Validity of the Danish National Patient Registry for Systemic Anticancer Treatment Registration from 2009 to 2019.
- Published in:
- Clinical Epidemiology, 2021, v. 13, p. 1085, doi. 10.2147/CLEP.S332776
- By:
- Publication type:
- Article
Pembrolizumab induced steroid resistant immune mediated colitis and concurrent Clostridioides difficile infection.
- Published in:
- Journal of Gastrointestinal & Liver Diseases, 2021, v. 30, n. 3, p. 411, doi. 10.15403/jgld-3923
- By:
- Publication type:
- Article
Durable response with lenvatinib and pembrolizumab combination therapy in a patient with pre-treated metastatic cholangiocarcinoma.
- Published in:
- Journal of Gastrointestinal & Liver Diseases, 2021, v. 30, n. 3, p. 409, doi. 10.15403/jgld-3730
- By:
- Publication type:
- Article
Safety, recommended dose, efficacy and immune correlates for nintedanib in combination with pembrolizumab in patients with advanced cancers.
- Published in:
- Journal of Experimental & Clinical Cancer Research (17569966), 2022, v. 41, n. 1, p. 1, doi. 10.1186/s13046-022-02423-0
- By:
- Publication type:
- Article
Adaptive antitumor immune response stimulated by bio-nanoparticle based vaccine and checkpoint blockade.
- Published in:
- Journal of Experimental & Clinical Cancer Research (17569966), 2022, v. 41, n. 1, p. 1, doi. 10.1186/s13046-022-02307-3
- By:
- Publication type:
- Article